Non alcoholic fatty liver disease (NAFLD) is one of the manifestations of the metabolic syndrome. The latter is mainly determined by the presence of overweight and type 2 diabetes, whose prevalence is rapidly raising in developed Countries (almost 40 % in adult US Americans in 2013 -2016) [1] in keeping with more food availability, cheap trash food, rich in fat, and soft drinks rich in sugar. The trend is even more worrisome, if one considers also the rapidly growing prevalence of children obesity. Given the magnitude of such a problem, expected to fully blow in the third decade of the third millennium, that we will be entering in less than 12 months, and the potential role of ultrasound in these patients a critical appraisal to this issue, as seen from the ultrasonographic standpoint, appears relevant.
recommend specific fibrosis slowing drugs in the future, whenever they will become available. Unfortunately, no easy and effective tool exist today for individual fibrosis staging, but among the various tools at hand, ultrasound-based techniques appear to play a prominent role, considering also elastography and Doppler techniques [4 -6] .
However a widespread use of ultrasound in this field faces big challenges. In fact, despite being the most convenient instrument for the assessment of NAFLD, ultrasound also suffers significant limitations that operators must be well aware of, to avoid erroneous management of such patients. ▪ Conventional gray scale ultrasound is not highly sensitive for the detection of early cirrhosis, especially before clinically significant portal hypertension has developed [6] ▪ The presence of fatty liver, with acoustic attenuation, may prevent adequate explorability of the entire parenchyma, particularly of the deepest areas, possibly preventing the recognition of the coarse cirrhotic echotexture and the detection of deeply seated focal liver lesions. Worth to remind that hepatocellular carcinoma occurring in a background of NAFLD develops before the progression to the cirrhotic stage in half of the cases [7] . Hence if limited explorability of the liver occurs, it has to be indicated in the report. ▪ The accuracy in the assessment of the liver profiles, which is a key feature to detect cirrhosis, is usually improved by the use of linear transducers, but this approach may become impossible when the thickness of the subcutaneous fat makes the liver too deep.
▪ Ultrasound shear wave elastography (SWE) is an extremely useful technique to suggest the presence of significant fibrosis or cirrhosis [4] . However, despite thresholds for such stages are known to be higher in NALFD than in viral chronic liver disease, precise values have not been definitively defined, differently from viral diseases [4] . ▪ Most informations on ultrasound SWE has been produced with Transient Elastography with Fibroscan. Using such equipment it is known that the XL probe produces slightly lower values than the M probe, but the failure rate in obese subjects is much lower. Attention is to be paid to indicate the utilized probe and to judge the measurement accordingly. ▪ The occurence of fatty infiltration can lead to overestimation of liver stiffness, expecially when the fatty infiltration is severe (even when only graded by conventional ultrasonography), by up to 2 -3 kPa [8] . This bias might be crucial in fibrosis estimation in the intermediate stages [9] . Indeed it was shown that additional information about the severity of fatty infiltration, such as those provided by the ultrasound based Controlled Attenutation Parameter (CAP), could contribute to provide more accurate fibrosis estimation in NAFLD patients [8, 10] . Hence future assessment of NAFLD patients should probably consider the assessment of the degree of severity of fatty infiltration. ▪ Very few other equipments beside Fibroscan have been assessed specifically in NAFLD patients having histology as reference standard [11] . Hence the estimation of staging by other non validated instruments is questionable. Only ruling out any significant fibrosis appears possibile, when liver stiffness is obsiously low (as a rule of thumb in the authors' view < 5 kPa). ▪ It has still to be proven if the distribution of fibrosis (and consequently the accuracy of ultrasound SWE) is homogeneous throughout the liver in NAFLD. Hence sampling in different right liver lobe areas might be recommended to better average the liver conditions. ▪ The failure rate of ultrasound SWE in overweight and obese subjects is reported to be higher than in normal weight subjects (on average the failure rate appears to be lower with pSWE technologies than 2 D.SWE on obese subjects, but at the price of higher dispersion of the values around the median) [11] . Quality indicator of Ultrasound SWE reliability have not been specifically developed in NAFLD and for most equipments they either do not exist at all or are provided but without any evidence compared to histological validation. Thus the ultrasound operator has little data to judge how reliable would be her/his stiffness estimations, expecially in case of fatty liver. ▪ The number of overweight and diabetic patients is enormous.
For this reason, even a small fraction of false positive cases would translate in a significant number of unneeded additional diagnostic investigations, carrying a risk of adverse events (e. g. in case of liver biopsy) or abuse of precious healthcare resources (e. g. portal vein pressure measurement, MRI elastography, etc). Therefore a screening of patients at high risk of advanced NAFLD related chronic liver disease, requiring ultrasound and SWE investigations, by simple non-invasive scores, appears recommended as for instance using simple clinical/laboratoristic scores, such as the NAFLD Fibrosis score. Prelimin-ary data with such strategy on a very large population of NAFLD patients (n = 800) repeatedly submitted to non invasive tests, including ultrasound transient elastography, and to to biopsy within the STELLAR studies has been presented in November 2018 [12] . Such series, beside the data on sequential use of non invasive tests, also showed a rate of 0.7 % of serious adverse events from biopsy with large needles, reinforcing the need for optimal strategies with noninvasive tests, among which ultrasound based techniques play a central role.
In conclusion ultrasound operators must pay significant attention to remain updated about the optimal and validated diagnostic work up for liver assessment in patients with metabolic syndrome and non alcoholic fatty liver disease to avoid the risk of poor patient management. 
